IL162166A0 - Compositions comprising epothilonesand their use for the treatment of carcinoid syndrome - Google Patents

Compositions comprising epothilonesand their use for the treatment of carcinoid syndrome

Info

Publication number
IL162166A0
IL162166A0 IL16216602A IL16216602A IL162166A0 IL 162166 A0 IL162166 A0 IL 162166A0 IL 16216602 A IL16216602 A IL 16216602A IL 16216602 A IL16216602 A IL 16216602A IL 162166 A0 IL162166 A0 IL 162166A0
Authority
IL
Israel
Prior art keywords
carcinoid syndrome
combination
treatment
epothilonesand
compositions
Prior art date
Application number
IL16216602A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IL162166A0 publication Critical patent/IL162166A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Epoxy Compounds (AREA)
IL16216602A 2001-12-13 2002-12-12 Compositions comprising epothilonesand their use for the treatment of carcinoid syndrome IL162166A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34216701P 2001-12-13 2001-12-13
US41599002P 2002-10-04 2002-10-04
PCT/EP2002/014162 WO2003049734A1 (en) 2001-12-13 2002-12-12 Compositions comprising epothilones and their use for the treatment of carcinoid syndrome

Publications (1)

Publication Number Publication Date
IL162166A0 true IL162166A0 (en) 2005-11-20

Family

ID=26992855

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16216602A IL162166A0 (en) 2001-12-13 2002-12-12 Compositions comprising epothilonesand their use for the treatment of carcinoid syndrome

Country Status (22)

Country Link
US (3) US20050020647A1 (https=)
EP (1) EP1463504B1 (https=)
JP (1) JP4672257B2 (https=)
KR (1) KR101010767B1 (https=)
CN (1) CN1602192A (https=)
AT (1) ATE330602T1 (https=)
BR (1) BR0214917A (https=)
CA (1) CA2468994A1 (https=)
CY (1) CY1105459T1 (https=)
DE (1) DE60212710T2 (https=)
DK (1) DK1463504T3 (https=)
ES (1) ES2266610T3 (https=)
HU (1) HUP0402537A3 (https=)
IL (1) IL162166A0 (https=)
MX (1) MXPA04005712A (https=)
NO (1) NO332773B1 (https=)
NZ (1) NZ533378A (https=)
PL (1) PL209147B1 (https=)
PT (1) PT1463504E (https=)
RU (1) RU2341261C2 (https=)
TW (1) TWI287986B (https=)
WO (1) WO2003049734A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999001124A1 (en) 1996-12-03 1999-01-14 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6204388B1 (en) 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
AU2003235761A1 (en) * 2002-01-14 2003-07-24 Novartis Ag Combinations comprising epothilones and anti-metabolites
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
CA2499682A1 (en) * 2002-10-09 2004-04-22 Kosan Biosciences, Inc. Epo d + 5-fu/gemcitabine
AU2004268377B2 (en) * 2003-09-02 2008-06-26 Novartis Ag Cancer treatment with epothilones
US20050171167A1 (en) 2003-11-04 2005-08-04 Haby Thomas A. Process and formulation containing epothilones and analogs thereof
AU2011255647A1 (en) 2010-05-18 2012-11-15 Cerulean Pharma Inc. Compositions and methods for treatment of autoimmune and other diseases
HUE071943T2 (hu) 2015-02-03 2025-10-28 Amryt Endo Inc Akromegália kezelése oktreotid orális alkalmazásával
RU2633266C2 (ru) * 2015-07-02 2017-10-11 Рауф Ашрафович Ашрафов Способ моделирования карциноидного синдрома
JP2025508846A (ja) * 2022-02-25 2025-04-10 アムリット・エンドゥ・インコーポレイテッド 疾患の治療のための経口オクトレオチド

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4356270A (en) * 1977-11-08 1982-10-26 Genentech, Inc. Recombinant DNA cloning vehicle
US4318477A (en) * 1980-09-22 1982-03-09 Kerpe Stase Z Pharmaceutical package
US5753616A (en) * 1986-11-10 1998-05-19 Biopure Corporation Method for producing a stable polymerized hemoglobin blood-substitute
DE3845000C2 (de) * 1987-07-10 1998-11-19 Novartis Ag Anwendung von Octreotid zur Behandlung von Brustkrebs
KR20000015944A (ko) * 1996-05-24 2000-03-15 팜 윌리암 엔. 신체 통로의 질병을 치료 또는 예방하기 위한조성물 및 방법
US5969145A (en) * 1996-08-30 1999-10-19 Novartis Ag Process for the production of epothilones and intermediate products within the process
DK1367057T3 (da) * 1996-11-18 2009-01-19 Biotechnolog Forschung Gmbh Epothiloner E og F
US6495579B1 (en) * 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
US6194181B1 (en) * 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
FR2775187B1 (fr) * 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
US6302838B1 (en) * 1998-02-25 2001-10-16 Novartis Ag Cancer treatment with epothilones
DE19908760A1 (de) * 1999-02-18 2000-08-24 Schering Ag Neue Epothilon-Derivate, Verfahren zu deren Herstellung und ihre pharmazeutische Verwendung
AU2001266583A1 (en) * 2000-05-26 2001-12-11 Kosan Biosciences, Inc. Epothilone derivatives and methods for making and using the same

Also Published As

Publication number Publication date
TWI287986B (en) 2007-10-11
PT1463504E (pt) 2006-10-31
NO332773B1 (no) 2013-01-14
DE60212710T2 (de) 2007-01-11
KR20040066893A (ko) 2004-07-27
HK1069983A1 (en) 2005-06-10
EP1463504A1 (en) 2004-10-06
PL369141A1 (en) 2005-04-18
TW200301113A (en) 2003-07-01
HUP0402537A3 (en) 2009-01-28
CN1602192A (zh) 2005-03-30
KR101010767B1 (ko) 2011-01-25
MXPA04005712A (es) 2004-12-06
HUP0402537A2 (hu) 2005-03-29
WO2003049734A1 (en) 2003-06-19
RU2004121687A (ru) 2005-08-10
JP4672257B2 (ja) 2011-04-20
US20050020647A1 (en) 2005-01-27
CY1105459T1 (el) 2010-04-28
ES2266610T3 (es) 2007-03-01
ATE330602T1 (de) 2006-07-15
JP2005511721A (ja) 2005-04-28
NO20042832L (no) 2004-07-05
DK1463504T3 (da) 2006-10-02
RU2341261C2 (ru) 2008-12-20
DE60212710D1 (de) 2006-08-03
US20060229345A1 (en) 2006-10-12
EP1463504B1 (en) 2006-06-21
AU2002366531A1 (en) 2003-06-23
BR0214917A (pt) 2004-11-30
CA2468994A1 (en) 2003-06-19
US20090246172A1 (en) 2009-10-01
NZ533378A (en) 2006-03-31
PL209147B1 (pl) 2011-07-29

Similar Documents

Publication Publication Date Title
ZA983618B (en) Novel cyclosporin derivatives their preparation and the pharmaceutical compositions which contain them
IL162166A0 (en) Compositions comprising epothilonesand their use for the treatment of carcinoid syndrome
CA2440111A1 (en) Combinations comprising an antidiarrheal agent and an epothilone or an epothilone derivative
WO2001072721A3 (en) Synergistic methods and compositions for treating cancer
PL1664041T3 (pl) Przydatne do leczenia bólu związki fenylowo-karboksyamidowe
WO1992019617A3 (en) Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
YU53402A (sh) Preparat
WO2004011477A3 (en) 6,11-4-carbon bridged ketolides
CL2004001050A1 (es) Compuesto derivado de 3'-[4-oxo-3-{[(ciclopropil o 2,2,2-trifluoroetil)amino]carbonil}-1,8-naftiridin-1(4h)-il]-3-sustituido-1-1'-bifenil-4-il; composicion farmaceutica; y uso en el tratamiento o prevencion de asma, bronquitis cronica, enfermedad pul
PL342614A1 (en) Anticarcinogenic drugs
EP1184035A3 (en) Use of growth hormone secretagogues for treatment of physical performance decline
GEP20074058B (en) 4-(7-halo-2-quino(xa) linyloxy-phenoxy-propionic acid derivatives as antineoplastic agents
MXPA04000567A (es) COMBINACIONES QUE COMPRENDEN EPOTILONAS Y SUS USOS FARMACeUTICOS.
EP2030618A3 (en) Combinations comprising epothilones and anti-metabolites
WO2001051055A3 (en) Pharmaceutical compositions containing steroidal structures and uses thereof
CA2501610A1 (en) Epothilone derivatives for the treatment of multiple myeloma
WO2002040477A3 (en) Saframycins, analogues and uses thereof
WO2006031719A3 (en) 1,4-bis-n-oxide-5,8-dihydroxyanthracenedione compounds and the use thereof
UA85199C2 (ru) Применение циклических пептидов типа анабенопептина для лечения состояний, при которых показано угнетение карбоксипептидазы u, производные анабенопептина и их промежуточные соединения
CA2501717A1 (en) Use of epothilone derivatives for the treatment of hyperparathyroidism
IL124128A (en) Composition comprising a benzoylphenylurea for treatment of topical fungal infection
TH69753A (th) องค์ประกอบซึ่งประกอบด้วยอีโพทิโลน และการใช้ของพวกมันสำหรับการรักษาเนื้องอกของทางเดินอาหาร
WO2001030328A3 (de) Verwendung von 2-amino-3,4-dihydro-chinazolinen zur herstellung eines medikaments zur behandlung oder prophylaxe von durch ischämischen zuständen bewirkten krankheiten
CA2478223A1 (en) Combinations comprising epothilone derivatives and alkylating agents
RU2004116067A (ru) Фармацевтические композиции, содержащие макролиды